FAKTOR-ZERTIFIKAT - BIOGEN IDEC | Real-time Bid/Ask 09:11:34 2024-06-27 EDT | ||
| 8.42 EUR / 8.52 EUR | -2.87% |
|
| 1 month | -9.54% | ||
| 3 months | -24.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 8.49 | -2.64% |
| 24-06-26 | 8.72 | +1.28% |
| 24-06-25 | 8.61 | +4.24% |
| 24-06-24 | 8.26 | -3.73% |
| 24-06-21 | 8.58 | +2.51% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 05:09 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | J.P. Morgan |
| WKN | JK4G0J |
| ISIN | DE000JK4G0J5 |
| Date issued | 2024-03-22 |
| Strike | 299.3 $ |
| Maturity | Unlimited |
| Parity | 8.44 : 1 |
| Emission price | 10.07 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.19 € |
|---|---|
| Lowest since issue | 7.27 € |
| Spread | 0.1 € |
| Spread % | 1.17% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
224.5
USD
Average target price
283.2
USD
Spread / Average Target
+26.15%
- Stock Market
- Certificates
- Certificat
